Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
April 20, 2019
Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study
Yasir Alayed, Andrew Loblaw, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 17, 2018
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation
Yasir Alayed, Patrick Cheung, Danny Vesprini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 6, 2021
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials
Rachel M Glicksman, Stanley K Liu, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 12, 2020
Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost
Yasir Alayed, Andrew Loblaw, Merrylee McGuffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)
Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 20, 2018
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey C Quon, Aldrich Ong, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 13, 2022
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Rohann J M Correa, Gerard Morton, Hans T Chung, et al.
Brachytherapy
|
June 25, 2019
MRI-based interstitial brachytherapy for vaginal tumors: A multi-institutional study on practice patterns, contouring, and consensus definitions of target volumes
Eric Leung, David D'Souza, Francois Bachand, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 3, 2022
GEC-ESTRO (ACROP)-ABS-CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina
Mitchell Kamrava, Eric Leung, Francois Bachand, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
International Journal of Radiation Oncology, Biology, Physics
|
April 20, 2019
Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study
Yasir Alayed, Andrew Loblaw, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 17, 2018
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation
Yasir Alayed, Patrick Cheung, Danny Vesprini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 6, 2021
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials
Rachel M Glicksman, Stanley K Liu, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 12, 2020
Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost
Yasir Alayed, Andrew Loblaw, Merrylee McGuffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)
Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 20, 2018
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey C Quon, Aldrich Ong, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 13, 2022
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Rohann J M Correa, Gerard Morton, Hans T Chung, et al.
Brachytherapy
|
June 25, 2019
MRI-based interstitial brachytherapy for vaginal tumors: A multi-institutional study on practice patterns, contouring, and consensus definitions of target volumes
Eric Leung, David D'Souza, Francois Bachand, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 3, 2022
GEC-ESTRO (ACROP)-ABS-CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina
Mitchell Kamrava, Eric Leung, Francois Bachand, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
Page
of 9